COVID-19 Alters Gray Matter Volume in the Brain

Summary: Gray matter was reduced in areas of the frontal gyri of patients with COVID-19. Significant gray matter reductions were seen in those who received oxygen therapy and in those who reported fever. The findings suggest coronavirus affects the frontotemporal brain network due to reduced oxygen and fever.

Source: Georgia Tech

Covid-19 patients who receive oxygen therapy or experience fever show reduced gray matter volume in the frontal-temporal network of the brain, according to a new study led by researchers at Georgia State University and the Georgia Institute of Technology.

The study found lower gray matter volume in this brain region was associated with a higher level of disability among Covid-19 patients, even six months after hospital discharge.

Gray matter is vital for processing information in the brain and gray matter abnormality may affect how well neurons function and communicate.

The study, published in the May 2021 issue of Neurobiology of Stress, indicates gray matter in the frontal network could represent a core region for brain involvement in Covid-19, even beyond damage related to clinical manifestations of the disease, such as stroke.

The researchers, who are affiliated with the Center for Translational Research in Neuroimaging and Data Science (TReNDS), analyzed computed tomography scans in 120 neurological patients, including 58 with acute Covid-19 and 62 without Covid-19, matched for age, gender and disease. They used source-based morphometry analysis, which boosts the statistical power for studies with a moderate sample size.

“Science has shown that the brain’s structure affects its function, and abnormal brain imaging has emerged as a major feature of Covid-19,” said Kuaikuai Duan, the study’s first author, a graduate research assistant at TReNDS and Ph.D. student in Georgia Tech’s School of Electrical and Computer Engineering.

“Previous studies have examined how the brain is affected by Covid-19 using a univariate approach, but ours is the first to use a multivariate, data-driven approach to link these changes to specific Covid-19 characteristics (for example fever and lack of oxygen) and outcome (disability level).”

The analysis showed patients with higher levels of disability had lower gray matter volume in the superior, medial and middle frontal gyri at discharge and six months later, even when controlling for cerebrovascular diseases. Gray matter volume in this region was also significantly reduced in patients receiving oxygen therapy compared to patients not receiving oxygen therapy.

Patients with fever had a significant reduction in gray matter volume in the inferior and middle temporal gyri and the fusiform gyrus compared to patients without fever. The results suggest Covid-19 may affect the frontal-temporal network through fever or lack of oxygen.

Reduced gray matter in the superior, medial and middle frontal gyri was also present in patients with agitation compared to patients without agitation. This implies that gray matter changes in the frontal region of the brain may underlie the mood disturbances commonly exhibited by Covid-19 patients.

This shows covid
The analysis showed patients with higher levels of disability had lower gray matter volume in the superior, medial and middle frontal gyri at discharge and six months later, even when controlling for cerebrovascular diseases. Image is in the public domain

“Neurological complications are increasingly documented for patients with Covid-19,” said Vince Calhoun, senior author of the study and director of TReNDS. Calhoun is Distinguished University Professor of Psychology at Georgia State and holds appointments in the School of Electrical and Computer Engineering at Georgia Tech and in neurology and psychiatry at Emory University.

“A reduction of gray matter has also been shown to be present in other mood disorders such as schizophrenia and is likely related to the way that gray matter influences neuron function.”

The study’s findings demonstrate changes to the frontal-temporal network could be used as a biomarker to determine the likely prognosis of Covid-19 or evaluate treatment options for the disease. Next, the researchers hope to replicate the study on a larger sample size that includes many types of brain scans and different populations of Covid-19 patients.

TReNDS is a partnership among Georgia State, Georgia Tech and Emory University and is focused on improving our understanding of the human brain using advanced analytic approaches. The center uses large-scale data sharing and multi-modal data fusion techniques, including deep learning, genomics, brain mapping and artificial intelligence.

About this neurology and coronavirus research news

Source: Georgia Tech
Contact: Anne Wainscott-Sargent – Georgia Tech
Image: The image is in the public domain

Original Research: Open access.
Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19” by K. Duan, et. al. Neurobiology of Stress


Abstract

Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19

COVID-19, the infectious disease caused by the most recently discovered severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global pandemic. It dramatically affects people’s health and daily life. Neurological complications are increasingly documented for patients with COVID-19.

However, the effect of COVID-19 on the brain is less studied, and existing quantitative neuroimaging analyses of COVID-19 were mainly based on the univariate voxel-based morphometry analysis (VBM) that requires corrections for a large number of tests for statistical significance, multivariate approaches that can reduce the number of tests to be corrected have not been applied to study COVID-19 effect on the brain yet.

In this study, we leveraged source-based morphometry (SBM) analysis, a multivariate extension of VBM, to identify changes derived from computed tomography scans in covarying gray matter volume patterns underlying COVID-19 in 120 neurological patients (including 58 cases with COVID-19 and 62 patients without COVID-19 matched for age, gender and diseases).

SBM identified that lower gray matter volume (GMV) in superior/medial/middle frontal gyri was significantly associated with a higher level of disability (modified Rankin Scale) at both discharge and six months follow-up phases even when controlling for cerebrovascular diseases. GMV in superior/medial/middle frontal gyri was also significantly reduced in patients receiving oxygen therapy compared to patients not receiving oxygen therapy.

Patients with fever presented significant GMV reduction in inferior/middle temporal gyri and fusiform gyrus compared to patients without fever. Patients with agitation showed GMV reduction in superior/medial/middle frontal gyri compared to patients without agitation. Patients with COVID-19 showed no significant GMV differences from patients without COVID-19 in any brain region.

Results suggest that COVID-19 may affect the frontal-temporal network in a secondary manner through fever or lack of oxygen.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.
  1. I got a flu around 1990, age 40, and came down with Chronic fatigue Syndrome and Fibromyalgia. Had the brain fog for 7 years before it went away. I dont get flu shots. Got another flu in May 2019. If I would get COVID -19, could I lose gray matter and have brain fog from this flu? When I was 3 years old, I received the polio vaccine. came down with all the symptoms of polio, but within the hour, I was back to normal. Have had allergies to drugs. asthma, 13-18 years old, age 40 for CFS/FM, and Allergy to Tylenol. Not allergic anymore to aspirin, penicillin, Tylenol. I am now 66. Do you think I should get this vaccine? Thank you.

Comments are closed.